With the upcoming stock split, you might want to check out this medical stock

WAN CHAI, Hong Kong - Sept. 12, 2022 - PRLog -- While the move garnered plenty of attention for DXCM, the market leader in continuous glucose monitoring (CGM) products will require more to turn things around.

CGM devices enable diabetic patients to continually monitor their blood glucose levels throughout the day, and DXCM is currently riding the wave of increased CGM use. However, the company's year-over-year revenue growth rate has slowed recently. That's not what investors want to see in a growth stock, especially in today's volatile global markets, especially when equities are being pummelled for anything resembling a legitimate cause.

Nonetheless, DXCM prospects are based on the continued expansion of the CGM sector. According to the Centres for Disease Control and Prevention (CDC) in the U.S., diabetes is a national pandemic that will only worsen in the upcoming decades.

This implies that creative firms like DXCM, which are always developing new methods to assist diabetic patients manage their chronic condition, will be in high demand. DXCM presently earns the majority of its revenues from the G6 CGM system and accessories, but it is seeking regulatory approval in the United States for its next-generation product, the G7; that device has already received regulatory approval in Europe. In terms of research, the G7 has outperformed itself.

DXCM conducted a clinical investigation in which over 300 diabetic patients were enrolled and over 39,000 blood-glucose level readings recorded using blood glucose meters were compared to those taken with the G7. The CGM device was within 20% of the verified glucose range 93% of the time. According to management, the G7's overall performance in this trial demonstrated its superiority over the G6.

In addition, the G7 will be 60% smaller than its predecessor. DXCM is banking on this gadget to help it gain traction in the underserved United States CGM market, as well as overseas markets with significantly lower CGM adoption. DXCM reported $628.8 million in sales in the first quarter, a 25% increase from the previous year.

The company's adjusted net income fell marginally to $32.3 million, down from $32.5 million in the first quarter of 2021. Despite its disappointing market performance this year, DXCM's leadership in the CGM area, along with the fact that the industry still has lots of white space, bodes well for the company's future.

Join our weekly latest newsletter in Finance, you may also visit us at Alpha Alliance Capital Limited through our website https://alphaalliancecapital.com/ or contact us via email.